OOIR: Observatory of International Research

Papers

(The H4-Index of Muscle & Nerve is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
COVID‐19–associated Guillain‐Barré syndrome: The early pandemic experience	183
Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis	110
COVID‐19 in patients with myasthenia gravis	82
Muscle ultrasound: Present state and future opportunities	80
COVID‐19–associated myositis with severe proximal and bulbar weakness	80
Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled	79
Small fiber neuropathy associated with SARS‐CoV‐2 infection	67
Metabolic syndrome and peripheral neuropathy	62
SARS‐CoV‐2–associated Guillain‐Barré syndrome with dysautonomia	61
Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study	55
Parsonage Turner syndrome after COVID‐19 vaccination	51
Guidelines on clinical presentation and management of nondystrophic myotonias	51
Combination molecular therapies for type 1 spinal muscular atrophy	50
Post COVID‐19 vaccine small fiber neuropathy	49
The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID‐19 pandemic	45
Clinical features of LRP4/agrin‐antibody–positive myasthenia gravis: A multicenter study	41
A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis	39
Neuralgic amyotrophy following infection with SARS‐CoV‐2	39
The Use of Telehealth to Enhance Care in ALS and other Neuromuscular Disorders	38
Amyotrophic lateral sclerosis care and research in the United States during the COVID‐19 pandemic: Challenges and opportunities	38
Risk factors for amyotrophic lateral sclerosis: A regional United States case‐control study	35
Guillain‐Barré Syndrome in a Patient With Minimal Symptoms of COVID‐19 Infection	33
Multisystem proteinopathy: Where myopathy and motor neuron disease converge	32
COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies	29
Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy	29

Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes	29
COVID‐19 in patients with myasthenia gravis: Epidemiology and disease course	28
Chronic inflammatory demyelinating polyradiculoneuropathy—Diagnostic pitfalls and treatment approach	28
Safety, feasibility, and efficacy of strengthening exercise in Duchenne muscular dystrophy	28